(#$QNRX) got FDA conditional approval for QYLEKI as the brand name for QRX003, its topical treatment for Netherton Syndrome, moving it closer to Phase 3 and a potential first‑in‑disease NDA.
#QuoinPharma #NethertonSyndrome #QRX003
prismmarketview.com/quoin-pharma...

“It’s not just a skin disease—it can be life-threatening.” @QuoinPharma (Nasdaq: $QNRX) spotlights the urgent pediatric need in Netherton Syndrome in a powerful new NETHERTON NOW episode featuring leading dermatologist Prof. Jemima Mellerio.
#NETHERTONNOW
prismmarketview.com/quoin-pharma...

#QuoinPharma #QNRX lands FDA Rare Pediatric Disease Designation for QRX003, targeting the life-threatening skin disorder Netherton Syndrome. The move brings QRX003 closer to a potential NDA and could earn Quoin a valuable Priority Review Voucher.

prismmarketview.com/quoin-pharma...

#QNRX just got the green light from the FDA to launch its second pivotal trial of QRX003 for Netherton Syndrome.
#QuoinPharma #NethertonSyndrome.

prismmarketview.com/quoin-pharma...

#QNRX QRX003 earns EMA Orphan Drug status - A major step forward in developing a much-needed treatment for Netherton Syndrome, a rare and debilitating skin disease.
#QuoinPharma
prismmarketview.com/quoin-pharma...